Monday, October 17, 2022 from 9:00 AM to 10:30 AM PDT at Continental Ballroom 4
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-22-171-L01-P
Activity Type: An Application-Based Activity
This session will have 3 speakers who will present an overview for the management of HF in the year 2022, and will focus on contemporary drug therapy management with a focus on telehealth and device technology.
 | Moderator: Douglas L. Jennings, Pharm.D., FCCP
Associate Professor, Department of Pharmacy Practice
Long Island University College of Pharmacy
Brooklyn, New York
View Biography |
Learning Objectives
1. Analyze the current evidence supporting novel drug therapies for heart failure across the spectrum of ejection fraction.
2. Describe strategies for how to transition HF patients to new evidence-based guideline-directed medications.
3. Construct comprehensive, evidence-based pharmacotherapy regimens for patients with heart failure across the spectrum of ejection fraction.
4. Evaluate process and data demonstrating how telehealth provides comprehensive heart failure medication management and improves medication adherence.
5. Discuss data and outcomes demonstrating how telehealth programs drive medication safety in the setting of polypharmacy.
6. Analyze social economic barriers and how to manage your patients’ costs and access to HF medications.
7. Discuss advances in durable device technology that have implications for drug therapy regimens.
8. Construct evidence-based drug therapy regimens for common complications such as gastrointestinal bleeding and thrombosis.
9. Evaluate opportunities for integrating novel heart failure drug therapies into the case of patients under durable LVAD support.